Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 3/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965225 | 0.89 | ACLY (0.44) | ADRA1ADRD2DRD3ACLYHTR6 | |
| SCHEMBL4214386 | 0.89 | HTR6 (0.52) | DRD2DRD3ACLYHTR6QRFPR | |
| SCHEMBL4201083 | 0.87 | DRD2 (0.42) | DRD2DRD3ACLYHTR6QRFPR | |
| SCHEMBL4209430 | 0.85 | HTR6 (0.42) | DRD2DRD3ACLYHTR6QRFPR | |
| SCHEMBL4211776 | 0.84 | CA1 (0.41) | ACLYHTR6QRFPRHTR1AHTR7 | |
| SCHEMBL13942853 | 0.83 | HTR6 (0.41) | DRD2DRD3ACLYHTR6QRFPR | |
| SCHEMBL4209428 | 0.82 | PPARG (0.40) | DRD2DRD3ACLYHTR6QRFPR | |
| SCHEMBL13942868 | 0.82 | CACNB4 (0.41) | ACLYHTR6QRFPR | |
| SCHEMBL4199329 | 0.81 | HTR6 (0.48) | ADRA1ADRD2DRD3ACLYHTR6 | |
| SCHEMBL4197752 | 0.72 | HTR6 (0.66) | DRD2DRD3ACLYHTR6QRFPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030038-A1 | Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor | HTR6, HTR1A, HTR1D | ADRA1A 72/4885DRD2 57/4885DRD3 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.